Mycobacterium intracellulare cDNA and Antigen

Mycobacterium intracellulare is a species of bacteria belonging to the Mycobacterium genus, which also includes Mycobacterium tuberculosis, the causative agent of tuberculosis. Mycobacterium intracellulare is known to cause opportunistic infections in humans, particularly in individuals with weakened immune systems, such as those with HIV/AIDS.

The 18 kDa antigen 2, 27 kDa lipoprotein antigen, and the 19 kDa lipoprotein antigen (lpqH) are important antigens produced by Mycobacterium intracellulare. These antigens are involved in the virulence and immune response of the bacterium. The 18 kDa antigen 2 is believed to play a role in the ability of the bacteria to evade the host immune response and survive within host cells. The 27 kDa lipoprotein antigen and the 19 kDa lipoprotein antigen (lpqH) are known to induce immune responses in the host, which can contribute to the immune defense against the bacterium.

These antigens are often targeted in diagnostic tests and vaccine development for Mycobacterium intracellulare infections. Antibodies against these antigens can be detected in blood samples of infected individuals, and they can also be used in the development of vaccines to stimulate the immune system to mount an effective immune response against the bacterium.

Overall, the 18 kDa antigen 2, 27 kDa lipoprotein antigen, and 19 kDa lipoprotein antigen (lpqH) are important components of the virulence and immune response of Mycobacterium intracellulare, and they are the subject of ongoing research to better understand their roles in the pathogenesis of this bacterium and to develop effective diagnostic and therapeutic strategies. So, they indeed play a crucial role in the virulence and immune response of Mycobacterium intracellulare.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The application of cDNA (complementary DNA) and recombinant antigens derived from M. intracellulare has been of interest for the development of diagnostic and vaccine tools for the control of infections caused by this bacterium.

Diagnostics: cDNA from M. intracellulare can be used to develop molecular diagnostic tools such as PCR (Polymerase Chain Reaction) assays for the rapid and specific detection of the bacterium in infected individuals. This is especially useful in cases where traditional culture methods are not feasible or are slow.

Vaccine development: Recombinant antigens of M. intracellulare have been investigated as potential vaccine candidates, but the development of a vaccine for infections caused by this bacterium is still in its early stages. More research is needed to determine the efficacy and safety of these antigens as vaccines.

Overall, the application of cDNA and recombinant antigens of M. intracellulare has the potential to contribute to the control and prevention of infections caused by this bacterium, which will benefit human and animal health by reducing the incidence of these infections.